Closing in on a leukaemia inhibitor
Cancer is the second leading cause of death globally. The most common paediatric cancer is a particularly aggressive type of blood cancer, B-cell acute lymphoblastic leukaemia (B-ALL). A genetic alteration is responsible for some of the cases and, recently, researchers discovered a molecule that may stop the rearranged sequence from activating its target genes. However, the question remains whether this inhibitor will prevent the transformation leading to the development of leukaemia. The IDEAL project is going to find out, testing the inhibitor in both cellular and animal models. These preclinical tests are an important step on the path to improving treatment and patient outcomes.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF-EF-SE - Society and Enterprise panel
See on map